{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:47:31Z","timestamp":1793339251400,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T00:00:00Z","timestamp":1513900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["15H04825"],"award-info":[{"award-number":["15H04825"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jjcc.2017.12.004","type":"journal-article","created":{"date-parts":[[2018,2,4]],"date-time":"2018-02-04T08:50:51Z","timestamp":1517734251000},"page":"471-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":158,"title":["A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity"],"prefix":"10.1016","volume":"71","author":[{"given":"Motoaki","family":"Sano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2017.12.004_bib0255","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0260","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0265","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0270","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1161\/01.CIR.0000129252.96341.8B","article-title":"Sympathetic drive in anterior and inferior uncomplicated acute myocardial infarction","volume":"109","author":"Graham","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0275","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/01.CIR.73.5.913","article-title":"Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure","volume":"73","author":"Leimbach","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0280","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/01.HYP.31.1.68","article-title":"Baroreflex control of sympathetic nerve activity in essential and secondary hypertension","volume":"31","author":"Grassi","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0285","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJM199212313272704","article-title":"Sympathetic overactivity in patients with chronic renal failure","volume":"327","author":"Converse","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0290","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1161\/01.CIR.0000103123.66264.FE","article-title":"Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension","volume":"108","author":"Huggett","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0295","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00125-005-1798-z","article-title":"Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome","volume":"48","author":"Grassi","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0300","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/00004872-199715120-00062","article-title":"The sympathetic nervous system and obstructive sleep apnea: implications for hypertension","volume":"15","author":"Narkiewicz","year":"1997","journal-title":"J Hypertens"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0305","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijcard.2008.03.056","article-title":"Increased muscle sympathetic nerve activity predicts mortality in heart failure patients","volume":"135","author":"Barretto","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0310","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/hc1102.105261","article-title":"Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease","volume":"105","author":"Zoccali","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0315","doi-asserted-by":"crossref","first-page":"M618","DOI":"10.1093\/gerona\/55.10.M618","article-title":"High urinary catecholamine excretion predicts mortality and functional decline in high-functioning, community-dwelling older persons: MacArthur Studies of Successful Aging","volume":"55","author":"Reuben","year":"2000","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"12 Pt 2","key":"10.1016\/j.jjcc.2017.12.004_bib0320","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/00004872-199816121-00019","article-title":"Role of the sympathetic nervous system in human hypertension","volume":"16","author":"Grassi","year":"1998","journal-title":"J Hypertens"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0325","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.autneu.2009.02.003","article-title":"Central sympathetic overactivity: maladies and mechanisms","volume":"148","author":"Fisher","year":"2009","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0330","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/01.HYP.30.5.1085","article-title":"Effect of sympathectomy on mechanical properties of common carotid and femoral arteries","volume":"30","author":"Mangoni","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0335","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0735-1097(01)01786-7","article-title":"Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation","volume":"39","author":"Hijmering","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0340","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00041552-200203000-00011","article-title":"Sympathetic nervous system and the kidney in hypertension","volume":"11","author":"DiBona","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0345","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/1440-1681.12725","article-title":"Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats","volume":"44","author":"Rahman","year":"2017","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0350","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2","volume":"35","author":"Matthews","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0355","doi-asserted-by":"crossref","first-page":"e002832","DOI":"10.1161\/JAHA.112.002832","article-title":"Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus","volume":"1","author":"Hillis","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0360","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jchf.2017.08.018","article-title":"Prognostic importance of temporal changes in resting heart rate in heart failure and preserved ejection fraction: from the TOPCAT Study","volume":"5","author":"Vazir","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0365","doi-asserted-by":"crossref","first-page":"457","DOI":"10.14740\/jocmr3011w","article-title":"Hemodynamic effects of sodium-glucose cotransporter 2 inhibitors","volume":"9","author":"Sano","year":"2017","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0370","doi-asserted-by":"crossref","DOI":"10.1111\/jdi.12726","article-title":"Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Sub-analysis of placebo controlled, double-blind clinical trials","author":"Sano","year":"2018","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0375","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0380","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0385","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1172\/JCI57301","article-title":"Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice","volume":"121","author":"Asada","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0390","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1681\/ASN.2015060647","article-title":"Severity and frequency of proximal tubule injury determines renal prognosis","volume":"27","author":"Takaori","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0395","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.semnephrol.2012.07.008","article-title":"Can we target tubular damage to prevent renal function decline in diabetes?","volume":"32","author":"Bonventre","year":"2012","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0400","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2337\/diab.43.5.629","article-title":"Increased renal metabolism in diabetes. Mechanism and functional implications","volume":"43","author":"K\u00f6rner","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0405","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"O\u2019Neill","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0410","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.kint.2016.08.025","article-title":"Progression of chronic kidney disease: too much cellular talk causes damage","volume":"91","author":"Gewin","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0415","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2337\/diacare.24.3.495","article-title":"Anemia with erythropoietin deficiency occurs early in diabetic nephropathy","volume":"24","author":"Bosman","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0420","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S2213-8587(16)30237-6","article-title":"SGLT2 inhibitors: \u03b2 blockers for the kidney?","volume":"4","author":"Gilbert","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0425","doi-asserted-by":"crossref","first-page":"844","DOI":"10.14740\/jocmr2760w","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0430","doi-asserted-by":"crossref","first-page":"341583","DOI":"10.1155\/2015\/341583","article-title":"Relevance of sympathetic nervous system activation in obesity and metabolic syndrome","volume":"2015","author":"Thorp","year":"2015","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0435","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/10641969509087053","article-title":"Mechanisms of insulin action on sympathetic nerve activity","volume":"17","author":"Muntzel","year":"1995","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0440","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1113\/jphysiol.2011.205575","article-title":"Insulin acts in the arcuate nucleus to increase lumbar sympathetic nerve activity and baroreflex function in rats","volume":"589","author":"Cassaglia","year":"2011","journal-title":"J Physiol"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0445","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1172\/JCI115842","article-title":"Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension","volume":"90","author":"Lembo","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0450","doi-asserted-by":"crossref","first-page":"R566","DOI":"10.1152\/ajpregu.00180.2013","article-title":"Selective leptin resistance revisited","volume":"305","author":"Mark","year":"2013","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0455","doi-asserted-by":"crossref","first-page":"E1682","DOI":"10.3390\/ijms18081682","article-title":"Sympathetic overactivity in chronic kidney disease: consequences and mechanisms","volume":"18","author":"Kaur","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0460","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/01.HYP.25.4.878","article-title":"Renal afferent denervation prevents hypertension in rats with chronic renal failure","volume":"25","author":"Campese","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0465","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0895-7061(02)02959-X","article-title":"Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity","volume":"15","author":"Ye","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0470","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00004872-198402040-00005","article-title":"Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog","volume":"2","author":"Katholi","year":"1984","journal-title":"J Hypertens"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0475","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1161\/01.CIR.0000034043.16664.96","article-title":"Sympathetic nerve activity in end-stage renal disease","volume":"106","author":"Hausberg","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0480","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0485","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin\u2013angiotensin blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0490","doi-asserted-by":"crossref","first-page":"e0144640","DOI":"10.1371\/journal.pone.0144640","article-title":"Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease","volume":"11","author":"Zhang","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0495","doi-asserted-by":"crossref","first-page":"9555","DOI":"10.1038\/s41598-017-09352-5","article-title":"Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats","volume":"7","author":"Ansary","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jjcc.2017.12.004_bib0500","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.jacc.2017.08.056","article-title":"Renal sympathetic denervation protects the failing heart via inhibition of neprilysin activity in the kidney","volume":"70","author":"Polhemus","year":"2017","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508717303477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508717303477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:58:15Z","timestamp":1760273895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508717303477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0914508717303477"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2017.12.004","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2017.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}